Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010
- 12 March 2012
- journal article
- Published by Wiley in Transfusion
- Vol. 52 (10) , 2113-2121
Abstract
BACKGROUND: Thrombotic events (TEs) are rare but often serious adverse events that could occur after administration of immune globulin (IG) products. Our study objective was to assess occurrence of recorded TEs after administration of different US‐licensed IG products and investigate potential risk factors using a large administrative database.STUDY DESIGN AND METHODS: This is a retrospective claims‐based cohort study of individuals exposed to IG products from January 1, 2008, through September 30, 2010, using HealthCore's Integrated Research Database, a longitudinal health care database. IG products were identified by recorded Healthcare Common Procedure Coding System codes. TEs were ascertained via International Classification of Diseases, Ninth Revision, Clinical Modification diagnosis codes. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for same‐day TEs by IG product, while controlling for confounders.RESULTS: Of 11,785 individuals exposed to IG products in the study period, 122 (1%) had TE(s) recorded on the same day as IG administration. TE rates per 1000 persons exposed ranged from 6.1 to 20.5 for different IG product groups. Vivaglobin users had an increased same‐day TE risk compared to reference Gammagard Liquid users (OR, 3.56; 95% CI, 1.54‐8.23). An increased TE risk was also found with older age (≥45 years), prior TE(s), and hypercoagulable state(s).CONCLUSION: The study suggests potentially elevated TE rates for different IG products, including subcutaneous. It also identifies important recipient TE risk factors and suggests that risk–benefit profiles should be weighed before IG administration. The observed differences may be due to various factors such as dosage, administration rates, and product manufacturing processes that warrant further evaluation.Keywords
This publication has 32 references indexed in Scilit:
- Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody‐mediated rejectionNephrology, 2011
- Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage studyBMC Medicine, 2011
- The New Generation of Liquid Intravenous Immunoglobulin Formulations in Patient Care: A Comparison of Intravenous ImmunoglobulinsPostgraduate Medicine, 2010
- Unlabeled uses of intravenous immune globulinAmerican Journal of Health-System Pharmacy, 2008
- The Estimation Power of Alternative Comorbidity IndicesValue in Health, 2008
- Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and ImmunologyJournal of Allergy and Clinical Immunology, 2006
- Risks associated with the use of intravenous immunoglobulin 1 1This review article reflects the opinions of the authors and not necessarily those of the U.S. Food and Drug Administration.Transfusion Medicine Reviews, 2003
- In vivo coagulation activation following infusion of highly purified factor XI concentrateBritish Journal of Haematology, 1997
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- Effect of high-dose intravenous immunoglobulin therapy on blood rheologyThe Lancet, 1992